<DOC>
	<DOCNO>NCT01805440</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled study investigational drug uridine treatment depress adolescent bipolar disorder ( i.e . `` bipolar depression '' ) . Participants initially randomize placebo complete 6-week protocol offer 6 month open-label uridine treatment follow-up . Participants initially randomize uridine offer open-label treatment well .</brief_summary>
	<brief_title>Uridine Adolescent Bipolar Depression Randomized Controlled Trial</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled study investigational drug uridine treatment depress adolescent bipolar disorder ( i.e . `` bipolar depression '' ) . In addition treatment investigational drug versus placebo , study include translational neuroimaging component : magnetic resonance spectroscopy ( 1H-MRS ) brain scan perform baseline , repeat follow 6 week treatment uridine placebo . The scan use radiation , perform 3 Tesla MRI system approve clinical use . The scan allow researcher measure concentration several chemical brain believe involved bipolar disorder depression . The primary hypothesis uridine treatment associate significant decrease GLX ( i.e . glutamate + glutamine ) level , compare placebo , part brain know anterior cingulate cortex . The secondary hypothesis decrease depressive symptom measure Children Depression Rating Scale-Revised ( CDRS-R ) Montgomery-Asberg Depression Rating Scale ( MADRS ) correlate reduction GLX . All participant complete initial 6-week protocol , include two brain scan , offer 6 month open-label treatment uridine .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<criteria>Participants 18 year age must able provide assent , permission parent guardian . Participants 18 year age old must able provide inform consent . Participants must age 13 21 year . Participants must meet DSM criterion Bipolar Disorder ( Type I , II , NOS ) , current mood state depress least 2 week . Participants must current Children 's Depression Rating ScaleRevised ( CDRSR ) score 45 great , and/or Montgomery/Asberg Depression Rating Scale ( MADRS ) score 25 great . Participants must meet DSM criterion primary psychotic disorder , developmental disorder substance use disorder . Participants must high risk suicidal homicidal action . Participants must pregnant breastfeeding . Participants must contraindication magnetic resonance imaging ( e.g . ferromagnetic implant , claustrophobic anxiety ) . Incarcerated person exclude , study approve Research Involving Prisoners .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Adolescent</keyword>
	<keyword>Bipolar Disorder</keyword>
	<keyword>Bipolar Depression</keyword>
	<keyword>Manic Depression</keyword>
	<keyword>Neuroimaging</keyword>
	<keyword>Magnetic Resonance Spectroscopy</keyword>
	<keyword>Uridine</keyword>
	<keyword>Pyrimidines</keyword>
</DOC>